SCHEMBL25907150

SCHEMBL25907150

COC(=O)C(O)(c1ccc(Cl)s1)c1ccc(Cl)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.38
DAO P14920 1/20 0.38
PPARA Q07869 1/20 0.38
SRC P12931 1/20 0.37
KMT2A Q03164 4/20 0.36
KDM4E B2RXH2 3/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 2/20 0.36
POLB P06746 1/20 0.36
KCNN4 O15554 1/20 0.36
MAPK1 P28482 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GSK3B P49841 1/20 0.35
ALDH1A1 P00352 3/20 0.33
LMNA P02545 3/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25908773 0.88 CHRM3 (0.42) KMT2AKDM4ETSHRMEN1POLB
SCHEMBL25907323 0.75 CHRM3 (0.39) LMNA
SCHEMBL4242263 0.75 SMN1; SMN2 (0.35) PPARAKMT2ATSHRMEN1MAPK1
SCHEMBL10746836 0.72 PPARA (0.50) F2DAOPPARAKMT2AKDM4E
SCHEMBL25907154 0.71 CHRM3 (0.37) F2
SCHEMBL826276 0.70 CHRM3 (0.49) SRCPOLBKCNN4GAASMN1; SMN2
SCHEMBL11841428 0.69 MEN1 (0.66) KMT2AKDM4ETSHRMEN1POLB
SCHEMBL6053314 0.69 KMT2A (0.42) F2PPARAKMT2AGSK3BALDH1A1
SCHEMBL13916203 0.69 SRC (0.40) SRCPOLBKCNN4NPSR1GAA
SCHEMBL25907218 0.68 CHRM3 (0.42) POLBNPSR1ALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-10-12 US disclosed
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-10-12 US disclosed
EP-4219485-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CYP3A43, ABCB1, ABCB11 F2 520/4885DAO 2631/4885PPARA 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.